View ValuationMedibank Private 향후 성장Future 기준 점검 2/6Medibank Private (는) 각각 연간 11.5% 및 5.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 28% 로 예상됩니다.핵심 정보11.5%이익 성장률11.40%EPS 성장률Insurance 이익 성장2.0%매출 성장률5.3%향후 자기자본이익률28.00%애널리스트 커버리지Good마지막 업데이트05 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.공지 • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026공지 • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.공지 • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.공지 • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.공지 • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.공지 • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.공지 • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025공지 • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australia공지 • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.공지 • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024공지 • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.공지 • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.공지 • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.공지 • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.공지 • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023공지 • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.공지 • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023이익 및 매출 성장 예측OTCPK:MDBP.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202810,0407457791,00156/30/20279,53170675086956/30/20269,014639-47379512/31/20258,770463226299N/A9/30/20258,663482269340N/A6/30/20258,556501311381N/A3/31/20258,446495432505N/A12/31/20248,335490554630N/A9/30/20248,182491682749N/A6/30/20248,030493811869N/A3/31/20247,939488N/AN/AN/A12/31/20237,848483326373N/A9/30/20237,623396234279N/A6/30/20237,398309143185N/A3/31/20237,261326N/AN/AN/A12/31/20227,124343729764N/A9/30/20227,114368821856N/A6/30/20227,105394913949N/A3/31/20227,117414693728N/A12/31/20217,130435472508N/A9/30/20217,081438460495N/A6/30/20217,032441447482N/A3/31/20216,930402547579N/A12/31/20206,829363647676N/A9/30/20206,804340595624N/A6/30/20206,779316543572N/A3/31/20206,836368451486N/A12/31/20196,892420358399N/A9/30/20196,829429N/A408N/A6/30/20196,765438N/A416N/A12/31/20186,381375N/A377N/A9/30/20186,479400N/A393N/A6/30/20186,577424N/A408N/A3/31/20187,010454N/A428N/A12/31/20177,006463N/A448N/A9/30/20176,977456N/A421N/A6/30/20176,948450N/A393N/A3/31/20176,914436N/A379N/A12/31/20166,879422N/A365N/A9/30/20166,843420N/A359N/A6/30/20166,807418N/A352N/A3/31/20166,791393N/A363N/A12/31/20156,774369N/A374N/A9/30/20156,728327N/A375N/A6/30/20156,682285N/A377N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MDBP.F 의 연간 예상 수익 증가율(11.5%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: MDBP.F 의 연간 수익(11.5%)이 US 시장(16.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: MDBP.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: MDBP.F 의 수익(연간 5.3%)이 US 시장(연간 11.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: MDBP.F 의 수익(연간 5.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MDBP.F의 자본 수익률은 3년 후 28%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YInsurance 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/12 07:54종가2026/05/08 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medibank Private Limited는 20명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrew AdamsBarrenjoey Markets Pty LimitedJohn HesterBell PotterFreya KongBofA Global Research17명의 분석가 더 보기
공지 • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.
공지 • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
공지 • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.
공지 • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.
공지 • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.
공지 • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.
공지 • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.
공지 • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025
공지 • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australia
공지 • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.
공지 • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024
공지 • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.
공지 • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.
공지 • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.
공지 • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.
공지 • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
공지 • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.
공지 • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023